Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review.
| Publicado en: | Targeted Oncology Vol. 19; no. 2; pp. 161 - 174 |
|---|---|
| Autores principales: | , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Mar2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=176250184&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 176250184 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 17762596 47DQ jtl: Targeted Oncology issn: 17762596 maglogo: N pubinfo: dt: Mar2024 vid: 19 iid: 2 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 176250184 175956272 10.1007/s11523-024-01040-5 176250184 ppf: 161 ppct: 13 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review. aug: au: Crotty, Patrick Kari, Karim Hughes, Griffin K. Ladd, Chase McIntire, Ryan Gardner, Brooke Peña, Andriana M. Ferrell, Sydney Tuia, Jordan Cohn, Jacob Haslam, Alyson Prasad, Vinay Vassar, Matt affil: https://ror.org/02mfxdp77 Office of Medical Student Research, Oklahoma State University Center for Health Sciences, 1111 W 17th St., 74107, Tulsa, OK, USA sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|